Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.00.

A number of brokerages have issued reports on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target on the stock.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its position in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after acquiring an additional 74,194 shares during the last quarter. Bellevue Group AG lifted its stake in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 142.9% in the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the period. BBR Partners LLC grew its position in shares of Altimmune by 4.5% during the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after acquiring an additional 16,271 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in Altimmune by 542.8% during the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after purchasing an additional 214,968 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Stock Down 1.7 %

Shares of NASDAQ ALT opened at $8.59 on Friday. The stock’s 50-day simple moving average is $7.65 and its two-hundred day simple moving average is $7.05. The firm has a market capitalization of $610.96 million, a P/E ratio of -5.54 and a beta of 0.15. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the firm earned ($0.39) EPS. As a group, research analysts anticipate that Altimmune will post -1.36 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.